| Year |
Citation |
Score |
| 2020 |
Lyons DO, Pullen NA. Beyond IgE: Alternative Mast Cell Activation Across Different Disease States. International Journal of Molecular Sciences. 21. PMID 32098318 DOI: 10.3390/Ijms21041498 |
0.354 |
|
| 2015 |
Orsolic I, Jurada D, Pullen N, Oren M, Eliopoulos AG, Volarevic S. The relationship between the nucleolus and cancer: Current evidence and emerging paradigms. Seminars in Cancer Biology. PMID 26721423 DOI: 10.1016/J.Semcancer.2015.12.004 |
0.316 |
|
| 2014 |
Faber TW, Pullen NA, Fernando JF, Kolawole EM, McLeod JJ, Taruselli M, Williams KL, Rivera KO, Barnstein BO, Conrad DH, Ryan JJ. ADAM10 is required for SCF-induced mast cell migration. Cellular Immunology. 290: 80-8. PMID 24950026 DOI: 10.1016/J.Cellimm.2014.05.005 |
0.362 |
|
| 2014 |
Morales JK, Saleem SJ, Martin RK, Saunders BL, Barnstein BO, Faber TW, Pullen NA, Kolawole EM, Brooks KB, Norton SK, Sturgill J, Graham L, Bear HD, Urban JF, Lantz CS, et al. Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses. Journal of Leukocyte Biology. 95: 643-50. PMID 24338630 DOI: 10.1189/Jlb.0913510 |
0.328 |
|
| 2013 |
Fernando J, Faber TW, Pullen NA, Falanga YT, Kolawole EM, Oskeritzian CA, Barnstein BO, Bandara G, Li G, Schwartz LB, Spiegel S, Straus DB, Conrad DH, Bunting KD, Ryan JJ. Genotype-dependent effects of TGF-β1 on mast cell function: targeting the Stat5 pathway. Journal of Immunology (Baltimore, Md. : 1950). 191: 4505-13. PMID 24068671 DOI: 10.4049/Jimmunol.1202723 |
0.351 |
|
| 2013 |
Villalta SA, Lang J, Kubeck S, Kabre B, Szot GL, Calderon B, Wasserfall C, Atkinson MA, Brekken RA, Pullen N, Arch RH, Bluestone JA. Inhibition of VEGFR-2 reverses type 1 diabetes in NOD mice by abrogating insulitis and restoring islet function. Diabetes. 62: 2870-8. PMID 23835340 DOI: 10.2337/Db12-1619 |
0.321 |
|
| 2013 |
Kay LJ, Gilbert M, Pullen N, Skerratt S, Farrington J, Seward EP, Peachell PT. Characterization of the EP receptor subtype that mediates the inhibitory effects of prostaglandin E2 on IgE-dependent secretion from human lung mast cells. Clinical and Experimental Allergy : Journal of the British Society For Allergy and Clinical Immunology. 43: 741-51. PMID 23786281 DOI: 10.1111/Cea.12142 |
0.33 |
|
| 2013 |
Atkinson JM, Pullen N, Johnson TS. An inhibitor of thrombin activated fibrinolysis inhibitor (TAFI) can reduce extracellular matrix accumulation in an in vitro model of glucose induced ECM expansion. Matrix Biology : Journal of the International Society For Matrix Biology. 32: 277-87. PMID 23369837 DOI: 10.1016/J.Matbio.2013.01.006 |
0.36 |
|
| 2012 |
Pullen NA, Falanga YT, Morales JK, Ryan JJ. The Fyn-STAT5 Pathway: A New Frontier in IgE- and IgG-Mediated Mast Cell Signaling. Frontiers in Immunology. 3: 117. PMID 22593761 DOI: 10.3389/Fimmu.2012.00117 |
0.322 |
|
| 2012 |
Elberg D, Turman MA, Pullen N, Elberg G. Prostaglandin E2 stimulates cystogenesis through EP4 receptor in IMCD-3 cells. Prostaglandins & Other Lipid Mediators. 98: 11-16. PMID 22503965 DOI: 10.1016/J.Prostaglandins.2012.03.005 |
0.349 |
|
| 2012 |
Falanga YT, Chaimowitz NS, Charles N, Finkelman FD, Pullen NA, Barbour S, Dholaria K, Faber T, Kolawole M, Huang B, Odom S, Rivera J, Carlyon J, Conrad DH, Spiegel S, et al. Lyn but not Fyn kinase controls IgG-mediated systemic anaphylaxis. Journal of Immunology (Baltimore, Md. : 1950). 188: 4360-8. PMID 22450804 DOI: 10.4049/Jimmunol.1003223 |
0.354 |
|
| 2012 |
Pullen NA, Barnstein BO, Falanga YT, Wang Z, Suzuki R, Tamang TD, Khurana MC, Harry EA, Draber P, Bunting KD, Mizuno K, Wilson BS, Ryan JJ. Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production. The Journal of Biological Chemistry. 287: 2045-54. PMID 22130676 DOI: 10.1074/Jbc.M111.311142 |
0.372 |
|
| 2012 |
Pullen NA, Anand M, Cooper PS, Fillmore HL. Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma. Journal of Neuro-Oncology. 106: 461-71. PMID 21858729 DOI: 10.1007/S11060-011-0691-5 |
0.591 |
|
| 2012 |
Birks S, Altinkaya M, Altinkaya A, Pilkington G, Kurian KM, Crosby C, Hopkins K, Williams M, Donovan L, Birks S, Eason A, Bosak V, Pilkington G, Birks S, Holliday J, ... ... Pullen NA, ... ... Pullen NA, et al. Abstracts from the 2012 BNOS Conference Neuro-Oncology. 14: ii1-ii12. DOI: 10.1093/Neuonc/Nos198 |
0.317 |
|
| 2010 |
Pullen NA, Fillmore HL. Induction of matrix metalloproteinase-1 and glioma cell motility by nitric oxide. Journal of Neuro-Oncology. 96: 201-9. PMID 19629394 DOI: 10.1007/S11060-009-9965-6 |
0.594 |
|
| 2010 |
Pullen NA, Anand M, Cooper PS, Fillmore HL. Abstract 2327: Functional investigation of glioblastoma pathology in the context of matrix metalloproteinase-1 tumor expression Cancer Research. 70: 2327-2327. DOI: 10.1158/1538-7445.Am10-2327 |
0.599 |
|
| 2009 |
Pullen N, Molloy E, Carter D, Syntin P, Clemo F, Finco-Kent D, Reagan W, Zhao S, Kawabata T, Sreckovic S. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody British Journal of Pharmacology. 157: 281-293. PMID 19366349 DOI: 10.1111/J.1476-5381.2009.00137.X |
0.32 |
|
| 2002 |
Saitoh M, Pullen N, Brennan P, Cantrell D, Dennis PB, Thomas G. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. The Journal of Biological Chemistry. 277: 20104-12. PMID 11914378 DOI: 10.1074/Jbc.M201745200 |
0.304 |
|
| 2002 |
Gonzalez-Garcia A, Garrido E, Hernandez C, Alvarez B, Jimenez C, Cantrell DA, Pullen N, Carrera AC. A new role for the p85-phosphatidylinositol 3-kinase regulatory subunit linking FRAP to p70 S6 kinase activation. The Journal of Biological Chemistry. 277: 1500-8. PMID 11684675 DOI: 10.1074/Jbc.M103808200 |
0.31 |
|
| 2000 |
Neve RM, Sutterlüty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells Oncogene. 19: 1647-1656. PMID 10763821 DOI: 10.1038/Sj.Onc.1203470 |
0.339 |
|
| Show low-probability matches. |